Miramistin 0.01% Solution, 500 ml
Scope of the drug
Dermatology
Release form
Solution
Manufacturer country
Russia
Package quantity, pcs
one
Scope of application
Dermatology
Miramistin 0.01% solution in fl.
500ml
Name ENG
MIRAMISTIN
Clinical and pharmacological group
Topical antiseptic
ATX code
Quaternary ammonium compounds
Dosage
0.01% x 500ml
Structure
1 ml of solution contains 0.1 mg miramistin
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
INN / Active ingredient
Benzyldimethyl 3- (myristoylamino) propylammonium chloride monohydrate
Specifications
Scope of the drug
Dermatology
Release form
Solution
Manufacturer country
Russia
Package quantity, pcs
one
Scope of application
Dermatology
Way of introduction
Vaginally
,
Locally
Vacation conditions
Without recipe
Volume, ml.
500 ml
Brand name
Infamed
The amount of the dosage form in the primary package
500 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiseptic
Anatomical and therapeutic characteristics
D08AJ Quaternary ammonium compounds
Dosage form
Topical solution
Packaging
Box
The target audience
Adult
Expiration date in days
1095
Package weight, g
550
Category
:
Antibiotics
,
Antiseptics and disinfectants
,
Disinfectants
Mode of application
:
In the treatment of purulent wounds and burns, the imposition of gauze dressings moistened with a solution of the drug is prescribed. < br> In the treatment of acute and chronic urethritis and urethroprostatitis, it is prescribed in combination with other drugs.
The solution is injected into the urethra in a volume of 2-5 ml 2-3 times / day for 5-7 days. < br> To prevent infection of postpartum injuries, tampons soaked in 50 ml of solution are injected intravaginally with an exposure of 2 hours for 7 days. < br> For the prevention of sexually transmitted diseases, 1.5-3 ml is injected into the urethra for men, -1-1.5 ml for women
in the vagina - 5-10 ml for 2-3 minutes
process the external genital organs, pubic skin. < br> < br>
Dosage (volume) of the substance in the preparation
:
Benzyldimethyl [3- (myristoylamino) propyl] ammonium chloride monohydrate (in terms of anhydrous substance) - 0.1 g